MX2011009478A - Dominio angiogenico de proteina secretada, acida, rica en cisteinas y metodos de uso. - Google Patents

Dominio angiogenico de proteina secretada, acida, rica en cisteinas y metodos de uso.

Info

Publication number
MX2011009478A
MX2011009478A MX2011009478A MX2011009478A MX2011009478A MX 2011009478 A MX2011009478 A MX 2011009478A MX 2011009478 A MX2011009478 A MX 2011009478A MX 2011009478 A MX2011009478 A MX 2011009478A MX 2011009478 A MX2011009478 A MX 2011009478A
Authority
MX
Mexico
Prior art keywords
tumors
seq
sparc
polypeptide
angiogenesis
Prior art date
Application number
MX2011009478A
Other languages
English (en)
Spanish (es)
Inventor
Vuong Trieu
Daniel Knauer
Neil Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2011009478A publication Critical patent/MX2011009478A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011009478A 2009-03-11 2010-03-11 Dominio angiogenico de proteina secretada, acida, rica en cisteinas y metodos de uso. MX2011009478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Publications (1)

Publication Number Publication Date
MX2011009478A true MX2011009478A (es) 2011-11-18

Family

ID=42729116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009478A MX2011009478A (es) 2009-03-11 2010-03-11 Dominio angiogenico de proteina secretada, acida, rica en cisteinas y metodos de uso.

Country Status (13)

Country Link
US (2) US20120087910A1 (enExample)
EP (1) EP2405932A4 (enExample)
JP (1) JP2012520081A (enExample)
KR (2) KR20110139256A (enExample)
CN (2) CN103724417A (enExample)
AU (1) AU2010224031B2 (enExample)
BR (1) BRPI1009457A2 (enExample)
CA (1) CA2755109A1 (enExample)
IL (2) IL215089A0 (enExample)
MX (1) MX2011009478A (enExample)
NZ (1) NZ595528A (enExample)
WO (1) WO2010105097A2 (enExample)
ZA (1) ZA201107415B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011224154A1 (en) * 2010-03-11 2012-09-27 Abraxis Bioscience, Llc SPARC angiogenic domain and methods of use
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN120361186A (zh) * 2025-04-15 2025-07-25 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
JP5590882B2 (ja) * 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質(sparc)
AU2008240117B2 (en) * 2007-04-13 2013-12-05 Abraxis Bioscience, Llc SPARC and methods of use thereof

Also Published As

Publication number Publication date
KR20110139256A (ko) 2011-12-28
CN103724417A (zh) 2014-04-16
AU2010224031B2 (en) 2013-05-02
JP2012520081A (ja) 2012-09-06
EP2405932A2 (en) 2012-01-18
US20140094416A1 (en) 2014-04-03
IL228795A0 (en) 2013-12-31
WO2010105097A2 (en) 2010-09-16
IL215089A0 (en) 2011-11-30
WO2010105097A8 (en) 2011-05-26
AU2010224031A2 (en) 2011-10-20
NZ595528A (en) 2013-10-25
US20120087910A1 (en) 2012-04-12
BRPI1009457A2 (pt) 2016-03-01
CN102482334A (zh) 2012-05-30
EP2405932A4 (en) 2012-08-22
ZA201107415B (en) 2012-06-27
WO2010105097A3 (en) 2010-11-04
KR20130043242A (ko) 2013-04-29
CA2755109A1 (en) 2010-09-16
AU2010224031A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
JP2021152073A (ja) Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US20140094416A1 (en) Sparc angiogenic domain and methods of use
US20130196929A1 (en) Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
JP2011149961A (ja) 骨髄およびリンパ系細胞癌の診断および処置
JP6509808B2 (ja) 脊索腫のための酵母系免疫療法
EP2630963A1 (en) SPARC angiogenic domain and methods of use
WO2018032501A1 (zh) 一种新的肿瘤特异性多肽及其应用
AU2013211470A1 (en) Sparc angiogenic domain and methods of use
AU2016243027A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
HK1194403A (en) Sparc angiogenic domain and methods of use
HK1167664A (en) Sparc angiogenic domain and methods of use
WO2025171109A1 (en) Cancer vaccines expressing post-translational modified antigens and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal